Review Article

Multimodal Liver-Directed Management of Neuroendocrine Hepatic Metastases

Table 3

Summary of outcomes for intraarterial therapy of neuroendocrine liver metastases. HAE: hepatic artery embolization; HACE: hepatic artery chemoembolization; HAI: hepatic artery infusion; OS: overall survival.

First author, publication yearNo. of embolized patientsSurvival dataComments

Paprottka, 2011 [50]42 [90Y radio-embolization]40 of 42 patients alive with mean followup of 16.2 months36 of 38 symptomatic patients had clinical improvement within 3 months
Dong, 2010 [51]123 [HACE]Mean OS: 39.6 months 5-year OS: 36%
10-year OS: 20%
Baseline albumin <3.5 g/dL was a multivariate predictor for poorer OS ( )
Kennedy, 2008 [52]148 [90Y radio-embolization]Median OS: 70 monthsNo radiation-induced liver disease or failure, even with retreatment
Christante, 2008 [49]77 [18 HAI alone, 59 HAI + HACE]Median OS [HAI alone]: 26 months
Median OS [HAI + HACE]: 39 months
All 10 patients with nonfunctional neoplasms and 15 of 16 patients with islet cell neoplasms died within 5 years
Strosberg, 2006 [53]84 [HAE]Median OS: 36 monthsFewer symptoms in 44 of 55 patients
Gupta, 2005 [54]123 [74 HAE, 49 HACE]Median OS [carcinoid]: 33.8 months
Median OS [islet cell]: 23.2 months
Male gender predicted worse OS ( ) for carcinoid, bone mets predicted worse OS for islet cell ( )